Adaptive Biotechnologies Corp (NASDAQ: ADPT) kicked off on Friday, up 6.50% from the previous trading day, before settling in for the closing price of $6.00. Over the past 52 weeks, ADPT has traded in a range of $2.28-$7.07.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 27.46% over the past five years. While this was happening, its average annual earnings per share was recorded 28.53%. With a float of $142.73 million, this company’s outstanding shares have now reached $147.56 million.
Let’s look at the performance matrix of the company that is accounted for 709 employees. In terms of profitability, gross margin is 53.84%, operating margin of -93.9%, and the pretax margin is -110.17%.
Adaptive Biotechnologies Corp (ADPT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Adaptive Biotechnologies Corp is 3.28%, while institutional ownership is 92.21%. The most recent insider transaction that took place on Nov 18 ’24, was worth 1,235. In this transaction Chief Financial Officer of this company sold 248 shares at a rate of $4.98, taking the stock ownership to the 154,330 shares. Before that another transaction happened on Aug 22 ’24, when Company’s SVP and General Counsel sold 26,922 for $4.50, making the entire transaction worth $121,079. This insider now owns 139,365 shares in total.
Adaptive Biotechnologies Corp (ADPT) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 28.53% per share during the next fiscal year.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Trading Performance Indicators
Take a look at Adaptive Biotechnologies Corp’s (ADPT) current performance indicators. Last quarter, stock had a quick ratio of 3.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.67.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.34, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.94 in one year’s time.
Technical Analysis of Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (NASDAQ: ADPT) saw its 5-day average volume 1.43 million, a positive change from its year-to-date volume of 1.41 million. As of the previous 9 days, the stock’s Stochastic %D was 24.85%. Additionally, its Average True Range was 0.50.
During the past 100 days, Adaptive Biotechnologies Corp’s (ADPT) raw stochastic average was set at 79.00%, which indicates a significant increase from 46.37% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.56% in the past 14 days, which was lower than the 83.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.48, while its 200-day Moving Average is $4.22. Nevertheless, the first resistance level for the watch stands at $6.65 in the near term. At $6.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $7.32. If the price goes on to break the first support level at $5.99, it is likely to go to the next support level at $5.58. Assuming the price breaks the second support level, the third support level stands at $5.32.
Adaptive Biotechnologies Corp (NASDAQ: ADPT) Key Stats
The company with the Market Capitalisation of 1.00 billion has total of 147,579K Shares Outstanding. Its annual sales at the moment are 170,280 K in contrast with the sum of -225,250 K annual income. Company’s last quarter sales were recorded 46,440 K and last quarter income was -32,070 K.
